The new antidepressants - Mechanisms of action

Australian Prescriber

Volumn 22, Issue 5, 1999, Pages 106-108

  Norman, Trevor R ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Repatriation Medical Centre   (Australia)

Author keywords

Nefazodone; Selective serotonin reuptake inhibitors; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUVOXAMINE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

AUSTRALIA; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG USE; HUMAN; SHORT SURVEY;

EID: 0032873438     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.1999.094     Document Type: Short Survey

References (4)

1. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997;8:410-31.
2. Wilde MI, Plosker GL, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993;46:895-924.
3. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-94.
4. Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53:608-36.